FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy
Related Topics >> Drug advertising | Effexor XR | FDA

Study: Psych drug ads misleading

Tools

Ads for psych drugs in medical journals are often misleading, a new study shows. Half the claims made in these ads offered no backup source that could be verified--and of those that were backed up by verifiable citations, almost half the cited studies didn't even support the claims. In some cases, the cited studies directly contradicted the ad's contentions. "When claims are made that aren't supported, the impression created is overly optimistic," lead author Glen Spielmans said.

Curiouser and curiouser, when the researchers asked nine drugmakers about the ads, only three replied, one of them to refuse to supply the sources of data it cited in its own advertising. That company? Wyeth. Ironically, the Effexor XR ad in question is actually headlined "See the data." Now you see it, now you don't.

- check out the study in the Journal of Nervous and Mental Disease
- see the item in Pharmalot

Related Articles:
Studies inflating antidepressant efficacy? Report
To DTC or not to DTC? Report
Does the FDA do enough to regulate drug ads? FDA report
10 reforms for drug advertising. Drug ad report

More stories about Drug advertising   Effexor XR   FDA  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 1 + 0?
To combat spam, please solve the math question above.